Deciphera Pharmaceuticals, Inc. (DCPH)

25.38 +0.01 (+0.04%) 收市：04:00PM EDT

Deciphera Pharmaceuticals, Inc.

200 Smith Street
Waltham, MA 02451
United States
781 209 6400
https://www.deciphera.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 355

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Steven L. Hoerter	President, CEO & Director	1.24M	無	1971
Mr. Thomas Patrick Kelly J.D.	Executive VP, CFO & Treasurer	772.47k	無	1971
Dr. Dashyant Dhanak Ph.D.	Executive VP & Chief Scientific Officer	498.45k	無	1963
Mr. Daniel C. Martin	Senior VP & Chief Commercial Officer	727.53k	無	1975
Dr. Matthew L. Sherman M.D.	Executive VP & Chief Medical Officer	870.58k	無	1956
Dr. Kevin Brodbeck Ph.D.	Senior VP & Chief Technical Officer	無	無	無
Jennifer Larson	Senior Vice President of Finance & Investor Relations	無	無	無
Mr. Jeffrey M. Held J.D.	Senior VP & General Counsel	無	無	無
Ms. Lisa Amaya Price	Senior VP & Chief Human Resources Officer	無	無	無
Ms. Jama Pitman	Senior VP & Chief Development Officer	無	無	1979

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

公司管治

截至 2024年5月1日 止，Deciphera Pharmaceuticals, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：7；董事會：6；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。